849217-77-2

Usage

Uses

Used in Pharmaceutical Industry:
1-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanecarboxylic acid is used as a pharmaceutical agent for its potential role in modulating biological processes and targeting specific pathways involved in various diseases. Its unique structure allows for interactions with cellular components, making it a candidate for the development of new therapeutic agents.
Used in Cancer Treatment:
In the field of oncology, 1-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanecarboxylic acid is used as an anticancer agent, exhibiting dose-dependent inhibition of tumor growth and tumor regression. Its mechanism of action involves the disruption of tumor vasculature and the induction of extensive tumor cell apoptosis, making it a promising candidate for cancer therapy.
Used in Drug Development:
1-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanecarboxylic acid is also used in drug development as a lead compound for the synthesis of new drugs. Its unique chemical properties and potential biological activities make it a valuable starting point for the design and development of novel therapeutic agents targeting a range of diseases.
Used in Chemical Research:
In the realm of chemical research, 1-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanecarboxylic acid serves as a subject of study for understanding its chemical behavior, reactivity, and potential applications in various chemical processes. Researchers can use 1-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanecarboxylic acid to explore new reaction pathways and develop innovative synthetic methods.

Upstream product

• 40258-99-9 1-(chlorocarbonyl)cyclopropane-1-carboxylic acid 
• 190728-25-7 4-((6,7-dimethoxyquinolin-4-yl)oxy)aniline 
• 598-10-7 cyclopropane-1,1-dicarboxylic acid 
• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 
• 123-30-8 4-amino-phenol 
• 1559-02-0 diethyl cyclopropane-1,1-dicarboxylate 
• 3697-66-3 1,1-cyclopropanedicarboxylic acid monoethyl ester 
• 35654-56-9 6,7-dimethoxy-4-chloroquinoline 
• 13425-93-9 6,7-dimethoxyquinoline-4-ol 

Downstream Products

• 1628530-38-0 ortho-hydroxycabozantinib 
• 1628530-41-5 meta-hydroxycabozantinib 
• 849218-30-0 N-[4-(aminomethyl)phenyl]-N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide trifluoroacetate 

Relevant academic research and scientific papers

BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF

The present disclosure relates to derivatives of bicyclic compounds and their uses in therapy. In particular, the present disclosure relates to derivatives of bicyclic compounds for use in modulating kinase enzymatic activity and accordingly modulating kinase-dependent diseases and conditions such as cancer and in specific embodiments, hepatocellular carcinoma (HCC). The present disclosure also relates to methods of synthesizing these compounds.

Preparation method for cabozantinib degradation impurity without p-fluoroaniline

The invention discloses a preparation method for a cabozantinib degradation impurity without p-fluoroaniline. The method comprises the following steps: preparation of 4-chloro-6,7-dimethoxyquinoline;preparation of an intermediate 1; and preparation of p-f

Preparation method of impurities in synthesis of cabozantinib malate

Belonging to the field of chemical pharmacy, the invention discloses a preparation method of impurities in synthesis of cabozantinib malate. The impurities include KB-2-A, KB-A and SM-3-B. The invention also provides a preparation method of impurity KB-2-

A synthesis method of card abundantly for nepal (by machine translation)

The present invention provides a card abundantly for nepal synthesis method, the method to 1, 1 - cyclopropyl dicarboxylic acid as the starting material, after the acylation with 4 - [(6, 7 - dimethoxy - 4 - quinolyl) oxy] aniline condensation, with 4 - f

A tyrosine kinase inhibitor and wherein the intermediate preparation method

The invention relates to a preparation method for a tyrosine kinase inhibitor and a midbody thereof. According to the method, a compound 1,1-cyclopropane dicarboxylic acid diester is taken as a raw material, and 1-((4-((6,7-dimethoxy quinoline-4-yl) oxy)

METHOD OF PREPARING FLUORINE-18 LABELED CABOZANTINIB AND ITS ANALOGS

The present invention relates to a method of preparing Cabozantinib (Cyclopropane- 1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylo]amide (4-fluoro- phenyl)amide) and 18F labeled Cabozantinib.

DOSING OF CABOZANTINIB FORMULATIONS

The invention relates to administration of various pharmaceutical formulations of N- (4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve des

METABOLITES OF N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE

The invention relates to metabolites of cabozantinib (I) as well as uses thereof.

C-MET MODULATORS AND METHODS OF USE

The present invention provides compounds, which have activity for modulating protein kinase enzymatic activity and are potentially useful for modulating cellular activities such as, e.g., proliferation, differentiation, programmed cell death, migration and chemoinvasion. The present invention also provides compositions containing such compounds, and methods for producing and using such compounds and compositions.

C-MET MODULATORS AND METHODS OF USE

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.